{'fraction_non_alphanumeric': 0.029840388619014575, 'fraction_numerical': 0.02498265093684941, 'mean_word_length': 5.4375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury

Acute cerebral lesions are associated with dysregulation of brain glucose homeostasis. Previous studies showed that knockdown of Na+‐D‐glucose cotransporter SGLT1 impaired outcome after middle cerebral artery occlusion and that widely expressed intracellular RS1 (RSC1A1) is involved in transcriptional and post‐translational down‐regulation of SGLT1. In the present study, we investigated whether SGLT1 is up‐regulated during traumatic brain injury (TBI) and whether removal of RS1 in mice (RS1‐KO) influences SGLT1 expression and outcome. Unexpectedly, brain SGLT1 mRNA in RS1‐KO was similar to wild‐type whereas it was increased in small intestine and decreased in kidney. One day after TBI, SGLT1 mRNA in the ipsilateral cortex was increased 160% in wild‐type and 40% in RS1‐KO. After RS1 removal lesion volume 1 day after TBI was reduced by 12%, brain edema was reduced by 28%, and motoric disability determined by a beam walking test was improved. In contrast, RS1 removal did neither influence glucose and glycogen accumulation 1 day after TBI nor up‐regulation of inflammatory cytokines TNF‐α, IL‐1β and IL‐6 or microglia activation 1 or 5 days after TBI. The data provide proof of principle that inhibition or down‐regulation of SGLT1 by targeting RS1 in brain could be beneficial for early treatment of TBI.